First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401

Reinhard Dummer(University Hospital of Zurich), Michele Maio(University of Siena), Erika Richtig(Medical University of Graz), Rudolf Herbst(Helios Klinikum Erfurt), Ralf Gutzmer(University Hospitals of the Ruhr-University of Bochum), Sandrine Mansard(Centre Hospitalier Universitaire de Clermont-Ferrand), Pier Francesco Ferrucci(MultiMedica), Massimo Guidoboni(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Célèste Lebbé(Inserm), Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Thierry Lesimple, Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), Michele Guida(Istituto Tumori Bari), Maurice Lobo(Bristol-Myers Squibb (United States)), Pippa Corrie(University of Cambridge), Jean‐Jacques Grob(Aix-Marseille Université), Silvia Sabatini(Azienda Ospedaliera S.Maria), Nicolás Meyer(Hôpitaux Universitaires de Strasbourg), Stéphane Dalle(Hospices Civils de Lyon), Tarek Meniawy(St John of God Subiaco Hospital), James Larkin(Trinity College Dublin), Margarita Askelson(Bristol-Myers Squibb (United States)), Karen Briscoe(Northern Cancer Institute), Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori), Muhammad Adnan Khattak(Edith Cowan University), Brigitte Dréno(Nantes Université)

Journal of Clinical Oncology

June 12, 2023

Cited by 25

|New England Journal of Medicine|2011|7.7k

|New England Journal of Medicine|2014|5.3k

|New England Journal of Medicine|2019|3.7k

|The Lancet|2012|3k

|New England Journal of Medicine|2014|2k

Related Papers